Massachusetts General Hospital

Approvals of BRAF-targeted therapies and immune checkpoint inhibitors have greatly expanded the melanoma treatment landscape during the past decade, according to a speaker at Chemotherapy Foundation Symposium.

Patients who underwent arthroscopic acetabular labral repair for cartilage damage with bone marrow aspirate concentrate had “significantly greater functional improvements” than those without bone marrow aspirate concentrate, results showed.

An obesity treatment model that utilizes integrated, treatment-focused care and combination therapy when appropriate can enhance patient outcomes without significantly increasing risk, according to a speaker.

A randomized phase 3 trial designed to evaluate elacestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer met both of its primary endpoints, according to the agent’s manufacturer.

Combination therapy is usually the best option to treat obesity, but it may take multiple attempts until the right combination is found, a speaker at the Obesity Medicine Association fall conference said.

In a recent editorial, researchers encouraged the normalization of medical emoji across the health care community, with the intent of providing accessible and effective means of communication to patients in the digital age.

The COVID-19 pandemic has exposed problems within U.S. health care systems that would be prudent to address now before another medical crisis surfaces, experts cautioned during a recent webinar hosted by U.S. News & World Report.

Obesity is a complicated disease resulting from interlocking causes that vary with each patient, including genetics, nutrition, hormones, medication, environment and sleep.

Researchers found no link between telestroke adoption and changes in stroke systems of care in a national sample of hospitals that implemented telestroke practices in EDs, according to a cross-sectional study published in JAMA Network Open.

Empagliflozin was safe and effective in patients with HF with reduced ejection fraction regardless of systolic BP or N-terminal pro-B-type natriuretic peptide level, according to two new analyses of results from the EMPEROR-Reduced trial.